|DoD Increases Development Contract With Cleveland BioLabs.|
|By Staff and Wire Reports|
|Friday, 01 July 2011 19:25|
Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced that it received a $1,531,034 increase (including option) in the development portion of the Company's existing contract, awarded on September 16, 2010, from the United States Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) Medical Identification and Treatment Systems (MITS) to fund additional development activities for CBLB502, a medical radiation countermeasure.
Alere Inc. (NYSE:ALR) ("Alere") announced today that it has closed senior secured credit facilities totaling $2.1 billion.
Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces that it has filed lawsuits in the U.S. District Court for the District of New Jersey against each of Amneal Pharmaceuticals, LLC ("Amneal") and Sandoz, Inc. ("Sandoz") for infringement of certain of Shire's VYVANSE patents.
Sorrento Therapeutics, Inc. (OTC Bulletin Board:SRNE) today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases.
Urigen Pharmaceuticals, Inc. (PINKSHEETS: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced a development update and management changes.